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Abstract
Background: Neurokinin-1 receptor (NK1R) antagonists have anti-HIV activity in monocyte-derived macrophages, decrease
CCR5 expression and improve natural killer cell function ex vivo. Aprepitant is a NK1R antagonist approved by FDA as an
antiemetic.
Methods: We conducted a phase IB randomized, placebo controlled, double masked study to evaluate the safety, antiviral
activity, pharmacokinetics and immune-modulatory effects of aprepitant in HIV-infected adults not receiving antiretroviral
therapy, with CD4+ cell count $350 cells/mm
3 and plasma viral load $2,000 copies/ml. Subjects were stratified by viral load
(, vs. $20,000 copies/ml) and randomized within each stratum to receive aprepitant at 125 mg QD(Low), or 250 mg
QD(High), or placebo(PL) for 14 days, and followed for 42 days.
Results: Thirty subjects were randomized and 27 completed treatment (9, 8, 10 subjects in 125 (Low), 250 (High), and PL
groups). 63% were male; 37% white; mean (SD) age 43 (9.3) years. Geometric mean baseline viral load (copies/ml) for Low,
High, and PL was 15,709, 33,013, and 19,450, respectively. Mean (95%CI) change in log10 viral load at day 14 for Low, High,
and PL was 20.02(20.24,+0.20), 20.05(20.21,+0.10), and +0.04(20.08,+0.16), respectively. The number of subjects with AEs
was 4(44.4%), 5(62.5%), and 1(10%) for Low, High, and PL. No Grade 4 AEs occurred.
Conclusions: Adverse events of aprepitant were more common in the treated groups. At the dose used in this two-week
phase IB study, aprepitant showed biological activity, but no significant antiviral activity.
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Introduction
The current paradigm of HIV treatment is the continuous use of
multiple antiretroviral drugs that target several steps of the life cycle
of the HIV virus. This strategy has been associated with substantial
decreases in the morbidity and mortality associated with HIV
infection[1]. Despite thesuccess ofantiretroviral therapy,treatment
failure occurs in many patients. In spite of the recent approval of
new classes of drugs for the treatment of HIV infection [2,3,4], it is
predictable that resistance will ultimately develop to these new
agents too, and that new antivirals will be required.
A continued challenge in anti-HIV drug development is to
make available antiretroviral agents with new target and
mechanisms of action and activity against drug-resistant virus.
Alternative paradigms for the treatment of HIV infection also
need to be explored. Recent studies have demonstrated the key
role that immune activation plays in the pathogenesis of HIV
infection and disease progression [5,6,7,8,9]. Patients with HIV
infection, even if successfully treated also have a high frequency of
neurocognitive impairment that it is associated with this residual
chronic inflammation [10,11].
The use of pharmacological agents and immunomodulators that
target this residual inflammation acting at the cellular level, rather
than at the HIV virus level might be useful in preventing
inflammatory and neurocognitive events associated with HIV
infection [12,13]. The use of neurokinin-1 receptors (substance P
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serve both purposes, as these compounds may have both antiviral
and immunomodulatory effects. Furthermore, these agents cross
the blood-brain barrier and have anti-depressive behavior activity.
Substance P (SP), a member of the tachykinin family [14]; plays a
central modulator role in neuroimmunoregulation, in particular, the
immune functions of mononuclear phagocytes, but also other
immune cells [15]. SP and its receptor, NK1R, may be important
and have modulatory effects in HIV-infected individuals. Our group
has demonstrated elevated plasma levels of SP in HIV-positive men
[16] in comparison with high-risk HIV-negative men, and also in
HIV positive women [17]. In a series of in vitro experiments we
demonstrated that SP-antagonists (CP-96,345) can inhibit HIV
replication in macrophages in a concentration dependent manner in
vitro [18]. We also have shown that this inhibition of HIV viral
replication is mediated to the binding of CP-96,345 to the NK1R and
may be mediated by a decreased expression of the HIV coreceptor
CCR5 [18]. In addition, we have demonstrated synergy of aprepitant
with other antiviral drugs [19] in ex vivo studied.
Preliminary data suggest that aprepitant, the only approved SP
antagonist has anti-HIV activity similar to CP-96,345 in the same
ex vivo system [20]. We studied the anti-HIV-l activity of
aprepitant against multiple macrophage tropic (R5) and T-cell
tropic (64) HIV-1 isolates grown in cell culture. Aprepitant had
the highest anti-HIV-1 activity of the NK1R antagonists examined
and was equally active against all major HIV-1 subtypes.
Aprepitant acted synergistically with protease inhibitors (ritonavir
and saquinavir), but not with nucleoside reverse transcriptase,
non-nucleoside reverse transcriptase, or viral entry inhibitors [19].
The purpose of this clinical trial was to determine the in vivo
safety and antiviral activity of aprepitant by comparing the change
in HIV RNA viral load after 2 weeks of aprepitant monotherapy
in patients with HIV infection not receiving any other antiretro-
viral treatment. The study was designed as a two-week trial as
mandated by the FDA in order to avoid emergence of resistance or
changes in tropism if aprepitant had significant antiviral activity.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design and study procedures
This was a phase IB randomized, placebo controlled, double
masked study to evaluate the safety, antiviral activity, pharmacoki-
netics and immune modulatory effects of aprepitant in HIV infected
adults not receiving antiretroviral therapy, with CD4+ cell count
$350 cells/mm
3 and plasma viral load $2,000 copies/ml. Thirty
patients with HIV-1 infection, not receiving antiretroviral therapy
were stratified by viral load (, vs. $20,000 copies/ml) and
randomized within each stratum to receive aprepitant 125 mg
QD(Low), 250 mg QD(High), or placebo (PL) for 14 days, and
followed for 42 days. The drug was masked by over encapsulation.
The investigators were blinded to the study assignment of the patients.
At the screening visit, previous antiretroviral treatment (if any)
was assessed, safety laboratory tests were conducted, and all
patients underwent testing for HIV-1 co-receptor tropism with the
use of a validated phenotypic tropism assay (Trofile, Monogram
Biosciences). Patients were also tested for plasma levels of HIV-1
RNA (Amplicor HIV-1 Monitor v1.5, Roche Diagnostics).
Participants were then randomized and evaluated at day 0, 3, 7,
10, 14, while they were receiving aprepitant or placebo, and at day
42, 4 weeks after discontinuing study medication. Additionally,
and 8 hour pharmacokinetic assessment was done after the first
dose and at day 14.
SP levels
SP immunoassay. A modified commercially available
antigen competition enzyme immunoassay (EIA) from Cayman
Chemical Company (Ann Arbor, MI) was used for the
quantitation of SP, as previously described [21].
Pharmacokinetics
A validated, liquid chromatography-tandem mass spectrometry
method was utilized for the quantification of aprepitant in HIV-
infected patients [22]. Both non-compartmental and population-
based (nonlinear mixed effect modeling) analyses were conducted
on aprepitant plasma concentration-time data. Non-compartmen-
tal results are presented herein. Peak (Cmax,T max) and exposure
metrics (AUC) were calculated using WinNonlin version 5.2
(Pharsight Corporation). PK data were summarized with descrip-
tive statistics and graphical presentation was made using
GraphPad Prizm version 4.
Viral Tropism
Viral tropism was assessed using the Trofile
TM assay. Samples
were shipped to Monogram Biosciences Inc., San Francisco, CA at
day 0 and 14 of the study to evaluate any changes in the tropism of
the HIV virus of the participants.
Objectives
Our primary objectives of the study were to assess the safety and
tolerability of two different doses of aprepitant for 2 weeks in HIV
infected individuals and to assess the response of plasma HIV-1
RNA. Our secondary objectives were to evaluate the dose-response
and pharmacokinetic and pharmacodynamic relationship between
viral RNA change and aprepitant plasma levels, the effects on CD4+
and CD8+ T-cell counts, circulating SP levels, , the effects of
aprepitant on viral tropism and to provide preliminary description of
any change mediated by aprepitant in sleep quality, anxious mood,
depressed mood and neurocognitive measures (using the Hamilton-
17 Depression Rating Scale (HAM-D-17), the Hamilton Anxiety
Scale (HAM-A) and the Pittsburgh Sleep Quality Index Score.
Subjects
We included HIV infected individuals, older than 18 years of
age, not receiving antiretroviral therapy for at least 16 weeks, with
CD4 cell count greater than 350 cells/mm
3, HIV RNA viral load
greater than 2,000 copies and an R5 tropic virus (Monogram). We
excluded individuals with a history of cancer and other serious
illness, pregnancy, chronic hepatitis B or C infection, individuals
with significant laboratory abnormalities, or were using steroids or
any other immunomodulators or chemotherapy. We also excluded
individuals with allergy or hypersensitivity to aprepitant.
The study was conducted at AIDS Clinical Trials Unit and the
Clinical and Translational Research Center (CTRC) of the
Hospital of the University of Pennsylvania in Philadelphia, PA,
USA. All patients signed a written informed consent. The study
was sponsored by the National Institutes of Mental Health,
approved by the IRB of the University of Pennsylvania, the US
Food and Drug Administration (IND#75,558), and registered in
Clinical Trials.gov #NCT00428519.
Statistical analysis
A sample size of 9 subjects within a dose group, gave us a 95%
probability to observe one or more adverse events assuming the
Phase IB Study of Aprepitant as an Anti-HIV Agent
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We allowed the substitution of participants that did not complete
the trial. The analyses of adverse events were primarily descriptive.
The number and percent of subjects with an adverse event were
calculated within each body system and overall for each of the
three treatment groups. The geometric mean viral load (copies/
ml) at baseline was calculated for each of the three treatment
groups. For viral load (log10), the mean and 95% confidence
intervals of the intra-individual difference (day 14 value minus day
0 value) was computed within each treatment group, whereas , for
SP, the percent change from baseline was computed. For CD4+
cell count, the geometric mean at each visit was calculated for each
of the three treatment groups. Linear mixed-effects models were fit
to examine the potential change over time in viral load and CD4+
at days 0, 3, 7, 10 and 14 among the three treatment groups. The
basic model has the viral load (or CD4+) as the outcome variable;
and treatment group, visit, and treatment-by-visit as explanatory
variables. Kruskal-Wallis nonparametric analysis of variance
(ANOVA) was used to compare viral load at day 42, CD4+ at
day 42, and SP at days 14 and 42 among the three treatment
groups. Fisher’s exact tests were used to compare the distribution
of the grade 2–4 adverse events among the three treatment groups,
and between the aprepitant-treated and the placebo groups.
Wilcoxon signed-rank test was performed for the paired
comparison of peak aprepitant concentration from 0 for each
treatment group at day 1 and day 14. Wilcoxon signed-rank test
was also performed for the paired comparison of peak aprepitant
concentration from day 1 to 14 within each treatment group.
Wilcoxon rank-sum test was used for the comparison of the
difference in peak aprepitant concentration at day 1 or 14 between
two aprepitant-treated groups. The P-values,0.05 were consid-
ered statistically significant. All data analyses were conducted using
SAS 9.2.
Results
Thirty subjects were enrolled with 10 being randomized into
each of the three treatment groups (125 mg, 250 mg, and
placebo), and 27 completed treatment (9, 8, 10 subjects in Low
(125 mg daily), High (250 mg daily), and placebo (PL), respec-
tively). 22 participants were naı ¨ve to antiretroviral therapy, eight
had prior experience. Table 1 summarizes the demographic
characteristics of the participants: 63% were male; 37% white;
mean (SD) age 43 (9.3) years. Half of them had HIV RNA viral
loads $20,000 copies/ml. Three subjects did not complete
treatment. One (40-year-old black female) in the 125 mg group
was discontinued due to prohibited concomitant medications. Two
subjects are in the 250 mg group: one (41-year-old black female)
was discontinued due to development of an exclusionary condition
(pneumonia) and another (48-year-old white male) withdrew at the
request of the subject (see Checklist S1).
Geometric mean viral load (copies/ml) at baseline for 125 mg
(Low), 250 mg (High), and PL was 15,709, 33,013, and 19,450
copies/mL. There were no statistically or clinically significant
changes in HIV RNA viral load in any of the three groups during
the drug or placebo administration (Figure 1A). The mean
(95%CI) change in log10 viral load at day 14 for Low, High, and
PL was 20.02(20.24,+0.20), 20.05(20.21,+0.10), and +0.04
(20.08,+0.16), respectively. The absolute and the CD4+ percents
were fairly stable across all study visits and did not differ
significantly by treatment group (Figure 1B).
Sixteen Grade 2 AEs and 1 Grade 3 AEs were reported
(excluding pre-existing and ongoing events). The number of
subjects with grade 2–4 adverse events (co-primary endpoint of the
study) was 4(44.4%), 5(62.5%), and 1(10%) for Low, High, and PL,
respectively (P=0.056). Subjects in the aprepitant-treated groups
experienced more grade 2–4 adverse events than that of the
placebo group (P=0.042). Neurological AEs were reported by 4
subjects in the High group (2 with headache, 1 with hypersomnia,
and 1 with lightheadedness and dizziness) and 1 subject in the Low
group (insomnia at 2 visits) (Table 2).
Mean values of SP concentration in plasma were relatively
stable in the placebo group during the study (Figure 2) but they
decreased moderately in both of the groups treated with
aprepitant. The mean [95% Cl] percent changes from day 0 to
day 14 for the groups treated with 125 mg/day and 250 mg/day
were 26.0% [214.4, 2.4] and 25.1% [215.9, 5.7], respectively.
The decrease of the mean SP plasma levels persisted in the 250 mg
Table 1. Demographic characteristics of study population.
Treatment Group
Characteristic 125 mg 250 mg Placebo
Number of subjects 10 10 10
Gender
Male 7(70%) 6(60%) 6(60%)
Age (years)
Mean (SD) 43.2 (9.5) 43.4 (8.2) 42.7 (10.9)
Ethnicity
Hispanic 0(0%) 0(0%) 1(10%)
Race
White 3(30%) 4(40%) 4(40%)
Black 7(70%) 5(50%) 6(60%)
Others 0( 0%) 1(10%) 0( 0%)
Viral load at screening (copies/Ml)
,20,000 5(50%) 5(50%) 5(50%)
$20,000 5(50%) 5(50%) 5(50%)
doi:10.1371/journal.pone.0024180.t001
Figure 1. Changes in mean viral load (panel A) and CD4 cell
count (panel B) by study arm. The grayed area represents the
dosing period.
doi:10.1371/journal.pone.0024180.g001
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changes between baseline values and the values measured at day
14 or day 42 in each of the active treatment groups were not
significantly different than the changes in the placebo group.
There were no statistically significant changes during the study in
the Hamilton Depression (HAM-D), Anxiety (HAM-A) scores and
the Pittsburgh Sleep Quality Index Score (data not shown).
Mean (+standard deviation) aprepitant plasma concentration
profiles for both dose groups are shown in Figure 3. Aprepitant
plasma levels are reasonably consistent following single dose
administration though somewhat more variable on day 14.
Individual peak aprepitant plasma concentrations (Cmax) on
days 1 and 14 are listed in Table 3 along with the mean and
standard deviation for all subjects. As expected, the aprepitant
concentration significantly increased from 0 in the 125 mg dose
group at day 1 (P=0.005) and day 14 (P=0.0077). Similarly, the
aprepitant concentration significantly increased from 0 in the
250 mg dose group at day 1 (P=0.0051) and day 14 (P=0.012).
As these data suggest, aprepitant accumulation significantly
increased from day 1 to 14 in the 250 mg dose group
(P=0.012). There was not a statistically significant change from
day 1 to 14 in the 125 mg dose group. Significant differences in
peak aprepitant concentration were observed between the 125 and
250 mg dose groups at day 1 (P=0.0009) and day 14 (P=0.0039).
Peak aprepitant concentrations occurred between 4 and 8 hours
post dose. There were no observed shifts in Tmax with either
dosing duration or amount.
There were no changes in the tropism of the HIV virus in study
participants. All participants’ viruses remained R5 tropic, as they
were at the initiation of the study.
Table 2. Number of Grade 2–4* adverse events reported.
Treatment Group
125 mg 250 mg Placebo
All Grade 2–4 Events (n=9) (n=8) (n=10)
Number of events 5 11 1
Number (%) of subjects 4 (44.4%) 5 (62.5%) 1 (10.0%)
* Protocol-defined co-primary endpoint.
Number (%) of Subjects with Grade 2–4 Adverse Events by Body System*
Treatment Group
125 mg
(n=9)
250 mg
(n=8)
Placebo
(n=10)
Total
(n=27)
Body system n (%) n (%) n (%) n (%)
Gastrointestinal 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.7)
Neurological 1 (11.1) 4 (50.0) 0 (0.0) 5 (18.5)
Ocular/Visual 1 (11.1) 0 (0.0) 0 (0.0) 1 (3.7)
Respiratory 0 (0.0) 0 (0.0) 1 (10.0) 1 (3.7)
Skin-Dermatological 1 (11.1) 1 (12.5) 0 (0.0) 2 (7.4)
Systemic 0 (0.0) 1 (12.5) 0 (0.0) 1 (3.7)
Uranalysis 1 (11.1) 1 (12.5) 0 (0.0) 2 (7.4)
* excludes pre-existing and ongoing events
doi:10.1371/journal.pone.0024180.t002
Figure 2. Plasma Substance P levels during the study.
doi:10.1371/journal.pone.0024180.g002
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Aprepitant (dosed at 125 and 250 mg daily for two weeks) was
safe in patients with HIV infection not receiving antiretroviral
therapy. Aprepitant showed biological activity, but not clinically
(or statistically) significant antiviral or immunologic improvement
at this dose range and duration of therapy. Adverse events were
more common in the aprepitant-treated groups, but the safety
profile was similar to patterns and frequency observed that in
HIV-uninfected patients treated for chemotherapy induced nausea
and vomiting.
We observed moderate declines of uncertain clinical or a
statistical significance in SP in both treated groups. SP enhances
inflammatory cytokine (TNF-a, IL-1 and IL-6) production by
immune cells such as macrophages through activation of NF-kB
[23].
The observed reduction of plasma SP levels is of interest, since
we have previously demonstrated increased levels of SP in men
[16] and women with HIV [17]
In another context, plasma SP levels have been studied in
relationship to neuropsychiatric disorders. SP levels are elevated in
the cerebrospinal fluid of patients with major depression [24] and
in patients post-traumatic stress disorder. SP levels are further
increased [24] by traumatic physiologic stimuli, but not by neutral
traumatic psychologic stimuli [24]. Recently we have shown that
SP has negative immunomodulatory properties in NK cell
function, that are restored by aprepitant and other NK1R
antabonist [25]
A significant proportion of individuals successfully treated with
antiretroviral therapy maintain elevated levels of immune
activation and inflammation 2–6 years after the initiation of
antiretroviral therapy [26,27,28]. It has become clear that chronic
inflammation plays a significant role in driving morbidity and
mortality in antiretroviral treated, virologically suppressed, HIV
infected individuals [29,30,31]. Patients with HIV infection, even
if successfully treated also have a high frequency of neurocognitive
impairment that it is associated with this residual chronic
inflammation [10,32]. The use of pharmacological agents that
target this residual inflammation may have a beneficial effect and
prevent the development of these long term neurocognitive
complications of HIV infection.
We did not observe changes in sleep quality, anxious mood,
depressed mood and neurocognitive measures. The absence of
changes in these parameters most likely reflects the lack of
significant pathologic characteristics at baseline in our study
Figure 3. Mean aprepitant plasma concentration on days 1 and 14 of the study.
doi:10.1371/journal.pone.0024180.g003
Table 3. Maximum aprepitant plasma concentrations (mg/
mL) observed on days 1 and 14 following once daily dosing of
125 and 250 mg QD to HIV-infected patients.
Cmax: 125 mg Cmax: 250 mg
Sub # Day 1 Day 14 Sub # Day 1 Day 14
103 1.17 1.23 102 1.65 7.44
205 0.83 1.52 206 4.08 4.46
105 0.98 1.20 107 1.67 3.84
109 1.35 2.08 207 1.94 9.07
111 1.37 1.09 110 1.90 3.60
113 1.34 0.96 210 0.99 1.67
211 1.05 1.63 114 1.73 6.66
213 1.06 0.80 214 2.28 8.01
202 0.83 7.26 201 4.04 –
209 0.69 – 106 1.62 –
All Subjects All Subjects
Mean 1.07 1.97 Mean 2.19 5.59
SD 0.24 2.02 SD 1.04 2.57
doi:10.1371/journal.pone.0024180.t003
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and depression. Neurokinin-1 receptor antagonists originally
showed promise as novel antidepressants [33]. However, large
clinical trials did not reveal evidence of efficacy in depression [34].
Aprepitant pharmacokinetic results in HIV-infected patients are
generally consistent with data previously published in healthy
volunteers [35] and in chemotherapy induced nausea and
vomiting patients (EMEND NDA [36]), albeit dosing is of shorter
duration for those indications. While these results are encouraging
with respect to the portability of the dose-exposure relationship
over acute dosing regimens, they must also be viewed with caution
when considering the higher doses and longer duration of therapy
projected necessary to treat HIV-infected individuals. Upon long-
term administration, as it has been shown both in animals and
humans, aprepitant induces its own metabolism resulting in
decreased exposure over time. Based on previous data in animals
and man, this occurs beyond 3 weeks of dosing. As aprepitant
displays dose- and time dependent pharmacokinetics, clearance
decreases with increased dose, likely due to saturable metabolism.
Absolute bioavailability decreases as the dose increases as well.
The decrease in clearance with dose is larger than the decrease in
bioavailability resulting in a more than proportional increase in
AUC with increased dose. A more detailed description of the PK
results relative to projected dose requirements in HIV-infected
patients is beyond the scope of this manuscript.
We propose several explanations of why aprepitant seems to
have an antiviral effect in vitro, however its in vivo effects seem to be
limited:
The dose used in this study is probably too low to see an
antiviral effect. The IC50 of aprepitant is approximately 5 mMi n
vitro (2.5 mg/ml) and the concentrations reached in this study
were clearly subtherapeutic. There are a number of strategies that
can be employed to boost the exposure of aprepitant to yield
exposures in the therapeutic range including the co-administration
of inhibitors of the p450 system such as ritonavir or cobicistat, as is
done with many antiretroviral drugs. The coadministation with
these boosters is expected to result in increased plasma levels of the
drug due to inhibition of the induction phenomenon that has been
reported in the past with extended aprepitant administration [37].
The duration of the administration of aprepitant was too short.
Because anti-inflammatory compounds do not target viral proteins
and act through an indirect mechanism it is not surprising that
they do not show antiviral activity after the short term
administration that characterize antiretroviral trials. We have
recently completed an in vivo study in Rhesus macaques
evaluating the antiviral activity of aprepitant in the setting of
SIV infection. The study was conducted in the Non Human
Primate center of Tulane University. Two groups of Rhesus
macaques (n=4 in each group) were infected with SIVmac251.
One group was untreated and served as control and the other
group received aprepitant (125 mg q.d.). There was a difference in
viral load set point of approximately 1 log that became apparent
only after 90 days of treatment with aprepitant (A. Lackner, S.D.
Douglas, J. Barrett, K. Lynch personal communication).
In conclusion, at the dose used in this exploratory phase IB
study, aprepitant was safe and showed biological activity but did
not show significant antiviral activity. Pharmacokinetic studies
showed concentrations could reach as high as 5.5 mg/ml without
enzymatic induction of the aprepitant metabolism although this
must be revisited over longer drug administration. Further studies
evaluating larger doses and/or co-administration of aprepitant
with ritonavir or cobecistat are planned. Hence, pharmacokinetic
strategies are possible to achieve higher exposure targets and
overcome any presumed liability due to nonlinearities in drug
clearance. A study of 375 mg of aprepitant daily in HIV infected
individuals is currently ongoing (clinicaltrials.gov # NCT
01300988). Future studies evaluating the therapeutic window of
aprepitant in Neuro AIDS patients at doses and study durations
targeted to show the multimodal effects demonstrated in vitro and
in preclinical models are necessary before proof-of-concept can be
established. The therapeutic goals for this class of compounds will
need to be defined in terms of their ability to improve both
virologic and neurocognitive outcomes.
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